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MicroRNAs (miRNAs) are a family of small non-coding RNA molecules of about 20–23 nucleotides in length, which negatively
regulate protein-coding genes at post-transcriptional level. Using a stem-loop real-time-PCR method, we quantified the expression
levels of 270 human miRNAs in 13 nasopharyngeal carcinoma (NPC) samples and 9 adjacent normal tissues, and identified
35 miRNAs whose expression levels were significantly altered in NPC samples. Several known oncogenic miRNAs, including
miR-17-92 cluster and miR-155, are among the miRNAs upregulated in NPC. Tumour suppressive miRNAs, including miR-34 family,
miR-143, and miR-145, are significantly downregulated in NPC. To explore the roles of these dysregulated miRNAs in the
pathogenesis of NPC, a computational analysis was performed to predict the pathways collectively targeted by the 22 significantly
downregulated miRNAs. Several biological pathways that are well characterised in cancer are significantly targeted by the
downregulated miRNAs. These pathways include TGF-Wnt pathways, G1-S cell cycle progression, VEGF signalling pathway,
apoptosis and survival pathways, and IP3 signalling pathways. Expression levels of several predicted target genes in G1-S progression
and VEGF signalling pathways were elevated in NPC tissues and showed inverse correlation with the down-modulated miRNAs.
These results indicate that these downregulated miRNAs coordinately regulate several oncogenic pathways in NPC.
British Journal of Cancer (2009) 100, 1002–1011. doi:10.1038/sj.bjc.6604948 www.bjcancer.com
& 2009 Cancer Research UK
Keywords: microRNA; target; pathway; nasopharyngeal carcinoma
                                             
MicroRNAs (miRNAs) are short non-coding RNA molecules
involved in post-transcriptional gene regulation (Ambros, 2004;
Bartel, 2004). In animals, miRNAs control the expression of target
genes by inhibiting translation or degradating target mRNAs
through binding to their 30UTR (Bartel, 2004). MicroRNAs have
been found to regulate genes involved in diverse biological
functions, including development, differentiation, proliferation,
and apoptosis (Ambros, 2004; Croce and Calin, 2005; Bushati and
Cohen, 2007).
Cumulative evidence suggests that miRNAs have major functions
in the pathogenesis of tumour. Approximately 50% of miRNAs are
localised in cancer-associated genome regions (Calin et al, 2004;
Sevignani et al, 2007). Biological characterisation also identified
several miRNAs function as tumour suppressors or oncogenes
(Chen, 2005; Croce, 2008). Large scale profiling revealed a global
alteration of miRNA expression patterns in human cancers (Lu
et al, 2005; Murakami et al, 2006; Kida and Han, 2008). Recently,
distinct miRNA expression signatures have been proposed as
diagnostic and prognostic markers for various types of human
cancer (Yanaihara et al, 2006; Schetter et al, 2008; Yu et al, 2008).
Although the biological effects of many miRNAs have been
characterised individually (Cimmino et al, 2005; Raver-Shapira
et al, 2007; Asangani et al, 2008), the impact of multiple miRNA
dysregulation on cellular functions and their roles in tumour
progression remain largely unknown. Proteomic and microarray
data reveal that although each miRNA may regulate up to
hundreds of genes, their effect on individual gene is moderate at
best (Lim et al, 2005; Baek et al, 2008; Selbach et al, 2008). Recent
studies suggest that multiple miRNAs may work in concert
to regulate related targets in a common pathway (Cloonan et al,
2008; Liu et al, 2008). Therefore, pathway analysis, rather than
individual target gene characterisation, may provide a better
solution to evaluate the biological consequences of global miRNA
dysregulation.
To link the miRNA profiling data with biological functions,
Gusev et al (2007) has developed a strategy, which calculates the
functions and pathways collectively regulated by the coexpressed
miRNA on the basis of computationally predicted targets. As all
target prediction algorithms generate certain fraction of false
positives, these false positives may significantly reduce the data
reliability when targets predicted for multiple miRNAs were
combined to calculate the functional pathways. Recent microarray
and proteomic data have provided valuable insights on target
prediction (Grimson et al, 2007). With these refinements
implemented in miRNA target prediction, the results of pathway
enrichment analysis on the basis of the coregulated targets should
provide a good insight into the functional role of dysregulated
miRNAs.
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approaches to assess the functional impact of miRNA dysregula-
tion in nasopharyngeal carcinoma (NPC). Differentially expressed
miRNAs were identified by profiling 270 human miRNAs in
clinical samples. Target prediction followed by pathway enrich-
ment analysis was conducted to identify the functional pathways
specifically regulated by the down-modulated miRNAs. Two
modifications were introduced to increase the confidence for
target prediction and enhance the specificity for pathway analysis.
The identified specific pathways were validated by the expression
data and in good agreement with earlier reported pathogenesis
in NPC.
MATERIALS AND METHODS
Tissue RNA preparation
Samples of NPC tissue and adjacent normal nasopharynx tissue
were obtained from patients undergoing surgery and were frozen
immediately after surgical resection. Collection and distribution of
tissue specimens were performed in accordance with the Institu-
tional Regulation Board of Chang Gung Memorial Hospital,
Taiwan. Total RNA was prepared using TRIzol reagent (InVitrogen,
Carlsbad, CA, USA) according to the manufacturer’s protocol. The
concentration of RNA was quantified using a NanoDrop Spectro-
photometer. The RNA integrity was evaluated by Agilent 2100
BioAnalyzer (Agilent Technologies, Palo Alto, CA, USA). RNAs
with an RNA integrity number (RIN) 47.5 were used for miRNA
and mRNA quantifications.
Reverse transcription (RT)
For miRNA quantification, a pulsed RT reaction, as described
by Chen et al (2005), was performed to convert all miRNAs
into corresponding cDNAs in one RT reaction. Briefly, 10-ml
reaction mixture containing miRNA-specific stem-loop RT
primers (final 2nM each), 500mM dNTP, 0.5ml Superscript III
(InVitrogen), and 1mg total RNA were used for the RT reaction.
The pulsed RT reaction was performed as follows: 161C for
30min, followed by 50 cycles at 201C for 30s, 421C for 30s, and
501C for 1s. To quantify mRNA transcripts, 1mg of total RNA
was converted into cDNA using a random hexamer as primer in a
10-ml reaction with the following conditions: 161C for 30min,
followed by 421C for 90min. Reverse transcription products
were diluted 20-folds before using for miRNA and mRNA Q-PCR
reactions.
Quantitative RT–(RT-qPCR) PCR
For miRNA quantification, 1ml of diluted RT product was used as
template for a 10ml PCR. Briefly, 1 SYBR Master Mix (Applied
Biosystem, Foster City, CA, USA), 200nM miRNA-specific forward
primer, and 200nM universal reverse primer were used for each
PCR reaction. The condition for Q-PCR is 951C for 10min,
followed by 40 cycles of 951C for 15s and 631C for 32s, and a
dissociation stage. Endpoint reaction products were analysed on a
10% polyacrylamide gel stained with ethidium bromide to
discriminate the correct amplification product (57–60bp) and
the potential primer dimmers (o44bp). For mRNA quantification,
the following PCR conditions were used: 951C for 10min, followed
by 45 cycles of 951C for 15s and 601C for 1min, and a dissociation
stage. All Q-PCR reactions were performed on an ABI Prism 7500
Fast Real-Time PCR system (Foster City, CA, USA).
Data analysis
The threshold cycle (Ct) is defined as the cycle number at which
the change of fluorescence intensity crosses the threshold of 0.2. Of
the 270 miRNAs evaluated, 47 showed the expression level below
the detection limit (Ct435) in more than 70% of samples, and
were excluded from the analysis. For the remaining 223 miRNAs,
raw Ct data were converted to 39 – Ct normalised by global median
normalisation before further analysis. For mRNA expression, the
average Ct of b-2-microglobulin, actin, and GAPDH was subtracted
from the raw Ct value to obtain d-Ct (dCt). The experimentally
normalised dCt values were converted to 39 – Ct used to analyse
the expression level of human mRNA transcripts.
Statistical analyses used for miRNA and mRNA expression data
including two-sample t-tests (two-tailed), paired-sample t-test
(two-tailed), Mann–Whitney test, principle component analysis,
Pearson’s correlation analysis, and hierarchical clustering were
performed with Partek Genomics Suite (version 6.3, St Louis, MO,
USA). Pathway enrichment analysis was performed using the
MetaCore database (GeneGO, St Joseph, MI, USA). P-values for
pathway enrichment analysis were calculated using the formula
for hypergeometric distribution and reflects the probability for
a pathway to arise by chance.
RESULTS
Identification of differentially expressed miRNA in human
NPC
The roles of miRNA dysregulation in the pathogenesis of NPC have
not been well explored. To identify miRNAs differentially
expressed in NPC, we analysed the expression levels of 270 human
miRNAs in 13 NPC and 9 normal nasopharyngeal tissues. These
samples include seven pairs of NPC and their adjacent normal
tissues from same patients. MicroRNA profiling was performed
using a stem-loop RT–qPCR method as described by Chen et al
(2005). The stem-loop RT–qPCR assay has been proven to offer
high sensitivity and specificity for the quantification of mature
miRNAs. The expression data of 47 miRNAs were eliminated from
further analysis because of their low abundance in all samples
tested (Ct435). Expression levels of the remaining 223 miRNAs
were expressed as 39 – Ct after global median normalisation.
Unsupervised hierarchical clustering analysis using expression
levels of all 223 detectable miRNAs in the seven paired normal–
NPC tissues generated a tree with normal and NPC samples clearly
separated into two groups (Figure 1A). To identify differentially
expressed miRNAs in normal and NPC tissues, two statistical tests
(two-sample t-test and Mann–Whitney rank test) were performed.
Expression of 35 miRNAs was significantly altered in NPC samples
(fold change: X3; false discovery rate: o0.05; Figure 1B). Among
them, 11 miRNAs, including miR-196b, miR-138, miR-155,
miR-142-3p, and miR-18a, were significantly upmodulated and
24 miRNAs, including miR-204, miR-449a, miR-34c-3p, miR-143,
and miR-145, were down-modulated in NPC samples. Complete
list of differentially expressed miRNAs and their chromosome
location are shown in Table 1. Similar results were obtained when
the miRNA expression levels were normalised using the geometric
mean of two reference miRNAs, miR-103 and miR-191, as
suggested by Peltier and Latham (2008;Supplementary Figure S1
and Supplementary Table S1).
To test whether the differentially expressed miRNAs selected
from paired samples show similar trend of alteration in unpaired
samples, we included two additional normal and six additional
NPC samples for the principal component analysis (PCA). As
shown in Figure 1C, the PCA analysis showed a complete
segregation between the 9 normal and 13 NPC samples.
Unsupervised hierarchical clustering with the 35 altered miRNAs
showed a clear separation between NPC and normal samples.
Expression levels of four most significantly upregulated miRNAs
and four most significantly down-modulated miRNAs in NPC
tissues were shown in Figure 2A and B. The global alteration in
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earlier reports on other human cancers (Lu et al, 2005; Muralidhar
et al, 2007).
In silico analysis of pathways specifically targeted by
down-modulated miRNAs
The profiling analysis indicated that a large number of miRNAs
are down-modulated in NPC tissues. As miRNAs are negative
regulators of protein-coding genes, down-modulation of these
miRNAs are expected to cause an upregulation of their target genes
and alterations of the associated cellular pathways in NPC tissues.
To estimate the overall effect of these down-modulated miRNAs on
cellular functions, we adopted a two-stage approach as depicted in
Figure 3A. The first stage was designed to identify target genes
coregulated by these down-modulated miRNAs. The second stage
performed a pathway enrichment analysis using the coregulated
targets to identify cellular functions specifically regulated by these
down-modulated miRNAs.
Most computational algorithms predict miRNA targets on the
basis of sequence complementarity and/or thermostability (Lewis
et al, 2003; John et al, 2004). However, recent studies indicated that
many additional factors, such as local AU content and site
position, can significantly affect the target site efficacy (Grimson
et al, 2007). The overall target efficacy can be expressed by a
context score. The correlation between context score and site
efficacy has been validated in both mRNA and protein levels
(Baek et al, 2008). Therefore, the concept of context score was
implemented to select high confidence targets for the down-
modulated miRNAs. The context score threshold for high efficacy
target was set at  0.2.
To identify coregulated targets for the down-modulated
miRNAs, we retrieved all target genes listed in the TargetScan
database (http://www.targetscan.org/; Lewis et al, 2003), which
includes targets for 456 miRNA families predicted by seed
sequence complementarity. Low confidence targets were elimi-
nated by filtering out targets with total context score greater than
 0.2. Two miRNAs, miR-34c-3p, and miR-30a* were not present
in the TargetScan database, and therefore were excluded from
further analysis. The 22 down-modulated miRNAs (‘down-miR’)
were used for target prediction and pathway analysis. To enhance
the specificity of the target and pathway analysis, a control set of
22 miRNAs (‘ctrl-miR’) was included in the target prediction and
pathway analysis. These 22 miRNAs showed constant expression
level in normal and NPC tissues and shared no sequence homology
in their seed regions with the 22 down-modulated miRNAs. The
seed sequence and the number of unique target predicted for
individual miRNA were listed in Table 2.
The number of total targets predicted for down-miR and
ctrl-miR was 8014 and 8039, respectively. Distribution of predicted
targets vs coregulating miRNAs for down-miR and ctrl-miR was
shown in Figure 3B. Within each target group, approximately half
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Figure 1 MicroRNA (miRNA) expression patterns distinguish normal from NPC tissues. (A) Unsupervised hierarchical clustering of 223 miRNAs in seven
normal (blue)–NPC (red) paired tissues. The hierarchical clustering was performed using squared Euclidean as distance measure and Ward’s method for
linkage analysis. MicroRNA levels were expressed as 39 – Ct after global median normalisation. (B) Selection of miRNAs differentially expressed in seven
paired normal–NPC tissues. Differentially expressed miRNAs were selected based on t-test (Po0.01) and median fold change (X3-fold). (C) Principle
component analysis using the expression levels of 35 miRNAs in 9 normal (blue) and 13 NPC (red) samples. (D) Unsupervised hierarchical clustering of 35
differentially expressed miRNAs in normal (blue) and NPC (red) samples. The hierarchical clustering was performed using Pearson’s dissimilarity as distance
measure and Ward’s method for linkage analysis. MicroRNA levels were expressed after standardisation.
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sTable 1 MicroRNAs significantly altered in NPC tissues
Mean expression
a P-value
MicroRNA Chromosome Normal NPC Fold change T-test Mann–Whitney
U-regulated
miR-196b 7p15 4.04 6.75 6.54 1.45E 04 2.68E 03
miR-138 3p21, 16q13 4.58 7.27 6.45 7.77E 04 4.04E 03
miR-155 21q21 7.50 10.09 6.04 2.05E 05 1.75E 03
miR-142-3p 17q22 9.43 11.73 4.92 6.95E 04 1.75E 03
miR-18a 13q31 5.20 7.50 4.92 6.00E 05 1.75E 03
miR-25
a 7q22 7.22 9.28 4.18 3.43E 05 1.75E 03
miR-205 1q32 16.01 18.02 4.00 1.51E 03 4.04E 03
miR-106a Xq26 9.25 11.18 3.80 2.37E 04 4.04E 03
miR-17 13q31 10.67 12.41 3.34 2.08E 03 8.81E 03
miR-15b
a 3q26 4.68 6.39 3.27 2.38E 04 1.75E 03
miR-17
a 13q31 5.15 6.84 3.22 4.40E 04 1.75E 03
Downregulated
miR-204 9q21 10.37 4.91  44.15 3.51E 07 1.75E 03
miR-449a 5q11 8.54 4.42  17.45 4.28E 05 2.68E 03
miR-34c-3p 11q23 11.92 8.15  13.64 1.55E 03 6.01E 03
miR-187 18q12 10.23 6.80  10.74 1.26E 04 1.75E 03
miR-145 5q33 16.77 13.39  10.42 7.03E 05 1.75E 03
miR-143 5q33 12.50 9.17  10.07 2.89E 05 1.75E 03
miR-34c-5p 11q23 9.30 6.04  9.63 2.49E 03 8.81E 03
miR-34b 11q23 8.36 5.37  7.92 5.74E 03 8.81E 03
miR-100 11q24 12.93 10.05  7.36 6.79E 04 1.75E 03
miR-9 1q22, 5q14, 15q26 7.16 4.34  7.07 7.34E 05 1.75E 03
miR-139-5p 11q13 11.59 8.83  6.75 1.18E 06 1.75E 03
miR-195 17p13 9.98 7.26  6.61 9.96E 05 1.75E 03
miR-148a 7p15 8.13 5.46  6.36 2.33E 04 2.68E 03
miR-30a
a 6q13 10.08 7.50  5.99 2.10E 03 8.81E 03
miR-497 17p13 12.12 9.63  5.62 1.64E 04 2.68E 03
miR-135a 3p21, 12q23 7.88 5.71  4.49 3.63E 03 4.04E 03
miR-130a 11q12 9.94 7.84  4.29 2.77E 04 2.68E 03
miR-31 9p21 12.53 10.51  4.05 1.50E 03 6.01E 03
miR-199b-5p 9q34 7.67 5.74  3.83 2.05E 03 6.01E 03
miR-200a 1p36 7.32 5.59  3.32 1.87E 03 4.04E 03
miR-29c 1q32 7.78 6.09  3.25 2.53E 03 1.27E 02
miR-152 17q21 10.30 8.65  3.13 1.04E 03 6.01E 03
miR-200b 1p36 12.01 10.36  3.13 1.59E 03 1.75E 03
miR-532-3p Xp11 13.52 11.92  3.03 4.10E 03 8.81E 03
aMean expression levels expressed as 39 – Ct.
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Figure 2 Significantly modulated MicroRNAs (miRNAs) in 9 normal and 13 NPC tissues. (A) Expression levels of four miRNAs significantly upregulated in
NPC tissues. (B) Expression levels of four miRNAs significantly downregulated in NPC tissues. Expression levels of miRNAs were expressed as 39 – Ct after
normalisation. P-value for each miRNA was calculated using two-tailed t-test.
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down-miR targets and 50% of the ctrl-miR targets). A majority of
targets were recognised by three or fewer miRNAs (85% of down-
miR targets and 90% of ctrl-miR targets). Between the two target
groups, more than 55% of predicted targets were shared by both
groups when the number of coregulating miRNA was equal or less
than three. However, when the number of coregulating miRNA was
equal or more than four, the fraction of overlapping targets
decreased to less than 20%. These results suggested that genes
coregulated by four or more miRNAs provided a better distinction
between the two target groups and were more suitable for
pathway-enrichment analysis.
The number of targets regulated by four or more miRNAs was
1223 and 838 for down-miR and ctrl-miR, respectively. These two
target groups were selected and uploaded into MetaCore for
pathway enrichment analysis. Statistically enriched pathways were
identified using a threshold P-value of 0.001. Sixty-five pathways
were found to be statistically enriched with the down-miR targets,
whereas only four pathways were enriched with the ctrl-miR
targets. For each pathway, we calculated the ratio of P-values
between down-miR and ctrl-miR to determine the specificity. With
a P-value ratio 41000 as the criteria, we identified 45 pathways
specifically enriched by down-miR targets. These specifically
targeted pathways include many pathways involved in tumour
pathogenesis, such as TGF-Wnt pathways, G1-S cell cycle
progression, VEGF signalling pathway, apoptosis and survival
pathways, and IP3 signalling pathways. The five most specifically
targeted pathways were shown in Figure 3D. Table 3 listed the
specifically targeted pathways grouped by their cellular functions.
Validation of genes specifically targeted by the
downregulated miRNAs
Regulation of G1/S transition and cross-talk between VEGF and
angiopoietin-1 signalling are the two most significantly pathways
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Figure 3 Analysis of collective regulated pathways. (A) Flow diagram depicting the process to identify the coregulated targets and specifically enriched
pathways. (B) Distribution of predicted targets regulated by down-miR and ctrl-miR. (C) Distribution of cumulative target number coregulated by multiple
microRNAs. (D) Pathways significantly and specifically enriched by down-miR targets.
Table 2 MicroRNAs selected for taget analysis
Seed
sequence Target
a
Seed
sequence Target
a
Down-miR Ctrl-miR
miR-100 ACCCGUA 44 miR-101 ACAGUAC 1063
miR-130a AGUGCAA 865 miR-103 GCAGCAU 759
miR-135a AUGGCUU 757 miR-129-3p AGCCCUU 480
miR-139-5p CUACAGU 650 miR-140-3p ACCACAG 857
miR-143 GAGAUGA 736 miR-146a GAGAACU 640
miR-145 UCCAGUU 956 miR-146b-5p GAGAACU 642
miR-148a CAGUGCA 808 miR-186 AAAGAAU 2030
miR-152 CAGUGCA 798 miR-193a-3p ACUGGCC 423
miR-187 CGUGUCU 85 miR-193b ACUGGCC 422
miR-195 AGCAGCA 1078 miR-194 GUAACAG 780
miR-199b-5p CCAGUGU 637 miR-24 GGCUCAG 768
miR-200a AACACUG 1255 miR-27b UCACAGU 1162
miR-200b AAUACUG 1393 miR-299-5p GGUUUAC 511
miR-204 UCCCUUU 1158 miR-320 AAAGCUG 1017
miR-29c AGCACCA 722 miR-324-5p GCAUCCC 341
miR-31 GGCAAGA 647 miR-362-5p AUCCUUG 493
miR-34b AAUCACU 618 miR-365 AAUGCCC 560
miR-34c-5p GGCAGUG 703 miR-483-3p CACUCCU 458
miR-449a GGCAGUG 716 miR-500 AAUCCUU 354
miR-497 AGCAGCA 994 miR-516a-5p UCUCGAG 622
miR-532-5p AUGCCUU 597 miR-550 GUGCCUG 417
miR-9 CUUUGGU 824 miR-654-3p AUGUCUG 494
aTargets predicted by the TargetScan using a threshold of total score o 0.2.
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stargeted by down-miR. To validate the effect of down-miR on these
two pathways in NPC, we selected three predicted target genes
from each pathway and compared their expression levels in
normal and NPC samples (Table 4). Real-time RT–PCR analysis
revealed that the expression levels of all six predicted targets,
including cyclin D2 (CCND2), cyclin E2 (CCNE2), CDC25A,
VEGFA, phospholipase C-g1 (PLCG1), and AKT3, were signifi-
cantly elevated in NPC tissues (Figure 4A and B). We also
examined the protein levels of CCNE2 in NPC tissue sections by
immunohistochemical staining to identify which cell type in the
tumour mass express cyclin E2 protein. Two representative cases
of cyclin E2 staining are shown in Figure 4C. Strong positive cyclin
E2 staining was detected in tumour cells (left panels), but not in
paired normal nasopharyngeal epithelium (right panels). This
result confirmed that the predicted targets of down-miR are
upregulated in NPC.
Table 3 Specifically targeted pathways
Gene number P-value
Category Pathway Total
a Down-miR Ctrl-miR Down-miR Ctrl-miR Ratio
Cytoskeleton remodelling TGF, WNT, and cytoskeletal remodelling 102 17 6 7.16E 08 4.77E 03 6.66E+04
Cytoskeleton remodelling 87 15 6 2.72E 07 2.16E 03 7.93E+03
ACM3 and ACM4 in keratinocyte migration 37 7 0 2.51E 04 1.00E+00 3.99E+03
Role of PKA in cytoskeleton reorganisation 39 8 2 4.90E 05 1.21E 01 2.47E+03
Cell cycle Regulation of G1/S transition 40 10 3 7.90E 07 2.33E 02 2.95E+04
Development Cross-talk between VEGF and angiopoietin-1 signalling 26 9 1 1.29E 07 3.33E 01 2.58E+06
Membrane-bound ESR1: interaction with G-proteins 45 10 0 2.55E 06 1.00E+00 3.93E+05
IGF-RI signalling 43 10 1 1.63E 06 4.88E 01 3.00E+05
Ligand-independent activation of ESR1 and ESR2 44 10 1 2.04E 06 4.96E 01 2.43E+05
G-protein-mediated regulation of MARK–ERK signalling 44 9 0 1.68E 05 1.00E+00 5.94E+04
A3 receptor signalling 47 9 0 2.95E 05 1.00E+00 3.39E+04
b-Adrenergic receptor signalling through cAMP 52 9 0 6.84E 05 1.00E+00 1.46E+04
Membrane-bound ESR1: interaction with growth facto 38 8 1 4.02E 05 4.47E 01 1.11E+04
Dopamine D2 receptor transactivation of EGFR 24 6 0 1.39E 04 1.00E+00 7.22E+03
Leptin signalling through PI3K-dependent pathway 46 9 2 2.46E 05 1.58E 01 6.42E+03
Notch activating pathway for NF-kB 25 6 0 1.77E 04 1.00E+00 5.65E+03
VEGF signalling through VEGFR2 – generic cascades 35 7 1 1.74E 04 4.20E 01 2.41E+03
VEGF signalling and activation 36 7 1 2.10E 04 4.29E 01 2.05E+03
A1 receptor signalling 50 8 1 3.07E 04 5.41E 01 1.77E+03
d-Type opioid receptor-mediated cardioprotecti 37 7 1 2.51E 04 4.38E 01 1.75E+03
ERBB family signalling 38 7 1 2.98E 04 4.47E 01 1.50E+03
GDNF family signalling 44 7 0 7.57E 04 1.00E+00 1.32E+03
Signal transduction AKT signalling 40 9 1 7.34E 06 4.64E 01 6.32E+04
Calcium signalling 43 9 2 1.38E 05 1.42E 01 1.03E+04
ERK interactions: inhibition of ERK 35 8 2 2.12E 05 1.01E 01 4.77E+03
IP3 signalling 49 9 2 4.19E 05 1.74E 01 4.16E+03
cAMP signalling 36 8 2 2.64E 05 1.06E 01 4.01E+03
PTEN pathway 45 7 0 8.71E 04 1.00E+00 1.15E+03
Apoptosis and survival BAD phosphorylation 41 8 1 7.17E 05 4.72E 01 6.59E+03
Transcription ChREBP regulation pathway 22 6 0 8.15E 05 1.00E+00 1.23E+04
CREB pathway 42 9 2 1.13E 05 1.37E 01 1.21E+04
Androgen receptor nuclear signalling 45 7 0 8.71E 04 1.00E+00 1.15E+03
PPAR pathway 60 9 2 2.15E 04 2.36E 01 1.10E+03
Immune response MIF – the neuroendocrine–macrophage connector 43 9 1 1.38E 05 4.88E 01 3.54E+04
PGE2 common pathways 52 9 2 6.84E 05 1.91E 01 2.79E+03
PIP3 signalling in B lymphocytes 42 8 2 8.59E 05 1.37E 01 1.59E+03
Cell adhesion Chemokines and adhesion 89 13 5 1.16E 05 1.19E 02 1.02E+03
G-protein signalling G-protein b/g signalling cascades 32 8 0 1.04E 05 1.00E+00 9.63E+04
G-protein a-Q signalling cascades 33 7 1 1.17E 04 4.02E 01 3.42E+03
aTotal gene number in the pathway.
Table 4 Targets selected for validation
Target gene
Expression level
a Coregulating miRNAs
Symbol Normal NPC P-value Down-miR Ctrl-miR
CCND2 10.87 14.06 o0.0001 miR-200a, 204, 29c, and 497 —
CCNE2 6.53 8.81 o0.0001 miR-195, 200a, 200b, 34c, 449, and 9 —
CDC25A 6.87 9.13 o0.0001 miR-100, 195, 34b, and 497 miR-103 and 27
AKT3 10.55 11.86 0.0232 miR-135a, 139, 195, 29c, 497, and 532 miR-140, 365, and 654
PLCG1 9.88 10.78 0.0135 miR-135a, 200b, 204, and 449 miR-140
VEGFA 11.87 13.57 0.0018 miR-195, 200b, 29c, and 497 miR-186
aExpression levels expressed as 39 – Ct values after normalisation with b-2-microglobulin, actin, and GAPDH.
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sThe 30UTR of cyclin E2 contains binding sites for many different
miRNAs. Six of them (miR-34c-5p, miR-449, miR-200a, miR-200b,
miR-195, and miR-9) were down-modulated in NPC (Figure 5A
and B). We further analysed the expression correlation between
three of the down-modulated miRNAs and cyclin E2 in 16 samples,
including 10 NPC and 6 normal nasopharyngeal tissues.
Expression of all three miRNAs showed significant inverse corre-
lation (Pearson’s correlation coefficient o 0.5, Po0.05) with the
expression level of cyclin E2 (Figure 5C). These results indicated
that the down-modulated miRNAs cooperatively upregulated
critical targets in the G1/S transition pathway. To determine
whether the expression level of CCNE2 is indeed regulated by
down-modulated miRNAs, we examined the mRNA and protein
level of CCNE2 in HK1 cells overexpressing one of the coregulating
miRNA, miR-9 (Figure 5D). As shown in Figure 5E and F, HK1/
miR-9 cells showed a significant decrease in CCNE2 mRNA and
protein levels, indicating that CCNE2 is a direct target of miR-9.
DISCUSSION
This study used a stem-loop RT–PCR method to quantify the
expression levels of 270 miRNAs in NPC tissues. Using a three-fold
change as the cutoff, we identified 35 miRNAs whose expression
levels were significantly altered in NPC tissues. Unsupervised
hierarchical clustering using these differentially expressed miRNAs
clearly segregated NPC tissues from the normal samples. Among
the differentially expressed miRNAs identified in this study, many
are known oncogenic or tumour-suppressive miRNAs previously
shown to be dysregulated in other cancer types (Chen, 2005; Croce,
2008). Our results provided further support for using miRNA
expression patterns as diagnostic markers.
The profiling analysis identified a group of miRNAs whose
expression was significantly down-modulated in NPC. To assess
the global impact of these down-modulated miRNAs, we
conducted a high stringency target prediction to identify potential
target genes, which were coregulated by multiple down-modulated
miRNAs, and then analysed the cellular pathways, which were
specifically enriched with these coregulated genes. Results from the
pathway enrichment analysis suggested that these down-modu-
lated miRNAs selectively target signalling cascades involved in cell
cycle regulation, cell survival and apoptosis, and cytoskeleton
remodelling. Quantification of target genes in clinical samples
confirmed the elevated expression of several coregulated targets,
and revealed a significant inverse correlation between the down-
modulated miRNAs and their targets. These results indicated that
the target prediction combined with pathway enrichment analysis
is an effective approach in investigating the influence of multiple
miRNAs.
Recently, Sengupta et al (2008) identified eight miRNAs
differentially expressed in NPC. Three of the most significantly
altered miRNAs, including miR-29c, miR-34b, and miR-34c, also
showed significantly reduced expression in our NPC samples.
However, the remaining five miRNAs identified in their study did
not show significant alteration in the current study. The discre-
pancy could be due to the difference in sample preparation or
difference between microarray and RT–PCR assay.
Expression of many oncogenic miRNAs, including miR-155,
miR-106a, and three miRNAs from the miR-17-92 cluster, were
found significantly elevated in NPC. The miR-155 upregulates the
NF-kB signalling pathway and is highly expressed in many
haematological malignancies and solid tumours (Rai et al, 2008).
MicroRNAs from the miR-17-92 cluster suppress multiple proli-
feration inhibitors as well as proapoptotic targets, and promote
tumour formation (Matsubara et al, 2007; Cloonan et al, 2008). The
upregulation of the miR-17-92 cluster is noted in leukaemia,
thyroid cancer, and lung cancer (Hayashita et al, 2005; Venturini
et al, 2007; Takakura et al, 2008).
The down-modulated mRNAs include miR-34b/miR-34c cluster,
the miR-143/miR-145 cluster, and the miR-195/miR-497 cluster.
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Figure 4 The upregulation of microRNA (miRNA) coregulated targets in NPC. (A) Quantification of coregulated targets in growth factor-regulated G1-S
cell cycle pathway : cyclin D2 (CCND2), cyclin E2 (CCNE2), and CDC25A. (B) Quantification of coregulated targets involved in VEGF pathway: VEGFA,
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p53 tumour suppressor network (Corney et al, 2007; Tarasov et al,
2007). Induction of miR-34b and miR-34c leads to apoptosis or
cellular senescence, whereas reduced miR-34b/c expression
attenuates p53-mediated cell death (Tarasov et al, 2007; Welch
et al, 2007). Reduced expression of miR-143 and miR-145 has been
documented in cervical cancer, colon cancer, and B-cell malig-
nancies (Michael et al, 2003; Akao et al, 2007; Wang et al, 2008).
Forced expression of miR-143 and miR-145 inhibit cell growth in
cervical cancer cells (Wang et al, 2008). Although the biological
function of miR-195 and miR-497 has not been characterised,
reduced expression of miR-195 and miR-497 on the 17p13 locus
has been documented in primary peritoneal carcinoma (Flavin
et al, 2008).
In addition to the commonly observed miRNAs, this study also
identified several dysregulated miRNAs whose aberrant expression
has not been reported before. For example, miR-25* was
significantly elevated in NPC and miR-532, and miR-199b-5p were
down-modulated. MiR-449 shared the same seed sequence with
miR-34c and was found down-modulated in our study. Similarly,
miR-152 shared the same seed sequence with miR-148a, and both
miRNAs were down-modulated in NPC.
Recently, two studies using microarray and proteomic approach
clearly showed that a single miRNA can regulate the expression of
hundreds of target genes (Baek et al, 2008; Selbach et al, 2008). The
widespread repression can be detected in both mRNA and protein
levels, but the degree of repression for individual target gene is
usually very mild. On the other hand, miRNA profiling analysis
typically uncovered aberrant expression of multiple miRNAs in the
diseased tissues (Lu et al, 2005). How to assess the biological
consequence of miRNA dysregulation has become a major
challenge. To overcome this difficulty, Gusev et al (2007) used a
computational approach to calculate the global pattern of cellular
functions and pathways affected by the coexpressed miRNAs.
In this study, we adopted the systems biology-based approach to
investigate the global impact of differentially expressed miRNAs in
the pathogenesis of NPC. Similar to the strategy described by
Gusev et al (2007), we analysed the major signalling pathways that
are most likely to be affected by the coexpressed miRNAs. Two
modifications were introduced to enhance our confidence in target
prediction and pathway analysis.
To enhance the accuracy for miRNA target prediction, we imple-
mented the ‘context score’ concept during the target prediction
process. Only genes with a total context score less than  0.2 were
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Figure 5 Inverse correlation between cyclin E2 expression with miR-34c, miR-200a, and miR-9 in NPC. (A) Predicted binding sites for miR-34c-5p,
miR-200a, and miR-9 on the 30UTR of cyclin E2. (B) Expression levels of miR-34c-5p, miR-200a, and miR-9 in normal and NPC tissues. (C) Correlation
analysis between cyclin E2 and three microRNAs. Pearson’s correlation coefficient and P-value for individual analysis are shown in the inserts.
(D) Quantification of miR-9 in HK1 cells after transduction with either negative control lentivirus (HK1/neg) or lentivirus encoding miR-9 (HK1/miR-9).
Levels of miR-9 and miR-16 were expressed as 39 – Ct.( E) Quantification of CCNE2 and b-2-microglobulin (B2M) transcripts in HK1/neg and HK1/miR-9
cells. Results are mean±s.d. of three independent experiments. A significant reduction in CCNE2 level was observed after miR-9 expression (HK1/neg vs
HK1/miR-9, CCNE2: P¼0.014, B2M: P¼0.258). (F) Reduced expression of CCNE2 protein in HK1/miR-9 cells.
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sincluded in our target pool. The concept of context score was first
proposed by Grimson et al (2007) to evaluate the site efficacy of
miRNA target using microarray data. The ‘context score’ combined
the complementarity of seed sequence, local AU content, site
position, and additional base pairing at the 30 site of miRNA to
evaluate the site efficacy between miRNAs and their targets. This
concept was further supported by the data from recent proteomic
studies (Baek et al, 2008).
To enhance the specificity of pathway enrichment analysis, we
selected a set of control miRNAs, which were not altered in NPC,
and conducted the target prediction and pathway enrichment
analysis in parallel. The probability of a gene targeted by multiple
miRNAs increases as the length of its 30UTR increases. This
potential bias introduced by genes with longer 30UTR can be
minimised by comparing it with the targets coregulated by the
control miRNAs. The pathway specificity was calculated by
comparing the P-values between these two target sets. This
strategy effectively addressed the complexity that arise from the
coexpressed miRNAs and coregulated targets.
Our studies revealed that the targets coregulated by the down-
modulated miRNA are specifically enriched with genes involved in
‘TGF-WNT and cytoskeletal remodelling’ pathways. Predicted
targets include several key regulators of the Wnt pathway, such
as WNT1, WNT2, frizzled homologue 3, 7, and 8, AKT, and
NF-kB1, as well as multiple extracellular matrix proteins, such as
collagen 4A1, 4A4, and fibronectin 1. Studies by Zeng et al (2007),
using profiling and immunohistochemical stains, shows that the
protein levels of these coregulated targets were significantly
elevated in NPC tissues, whereas elevated expression of extra-
cellular matrix proteins was shown by Sengupta et al (2008) using
Q-PCR. The analysis is consistent with the observation that WNT
signalling pathway is abnormally regulated in NPC (Shi et al, 2006;
Zeng et al, 2007; Chou et al, 2008).
Another pathway preferentially targeted by the down-modulated
miRNAs involved growth factor-regulated G1-S cell cycle progres-
sion. Several cell cycle regulators, including cyclin D2, cyclin E2,
and CDC25A are coregulated by the downregulated miRNAs.
Reverse transcriptase PCR analysis confirmed the elevated
expression of these target genes in NPC tissues. Correlation
analysis further revealed a significant inverse correlation between
the level of cyclin E2 and three of its cognate miRNAs, miR-34c,
miR-200a, and miR-9. These results suggest that the aberrant cell
cycle control in NPC tissues may be tightly linked to the
dysregulated expression of miRNAs (Hwang et al, 2002; Tao
et al, 2005; Chou et al, 2008).
The third signalling pathway, significantly targeted by down-
modulated miRNAs, is the VEGF-regulated angiogenesis. Predicted
targets include VEGF-A, PLC-g, and AKT. Earlier studies have shown
that VEGF is widely expressed in NPC tissues, and elevated VEGF
expression is associated with local recurrence and distal metastasis
(Li et al, 2008; Pan et al, 2008). Current studies revealed that
several key regulators on the VEGF-regulated signalling pathway are
cotargeted by multiple miRNAs, including miR-135a, miR29c, miR-
195, and miR-497. Simultaneous down-modulation of these miRNAs
may be responsible for the elevated VEGF signalling in NPC.
Recent studies using an miRNA target reverse screening method
showed that miR-16 family triggers a cell cycle arrest by silencing
multiple cell cycle regulatory genes simultaneously (Liu et al,
2008), rather than the individual target. Similarly, miR-17-5p
regulates the cell cycle progression by coordinately suppressing
more than 20 genes involved in the G1/S transition (Cloonan et al,
2008). It is evident that a better connection between cellular
function and miRNA expression requires both computational
as well as experimental approach. The context score filter and the
use of control gene list significantly increased our confidence for
target prediction and pathway analysis. Experimental validation
and literature mining confirmed that the expression data detected
in clinical samples are consistent with the computational predic-
tion. This study has shown the systems biology approach as
a valuable tool to uncover global functional change associated
with miRNA dysregulation. Similar approach can be used to assist
the functional interpretation of miRNA expression data in other
human diseases.
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